Highline Capital Management, L.P. Alector, Inc. Transaction History

Highline Capital Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$14.84 - $22.23 $378,538 - $567,042	-25,508 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$9.4 - $16.7 $566,810 - $1.01 Million	-60,299 Reduced 70.27%	25,508 $386,000
Q3 2020 Nov 16, 2020	BUY	$10.54 - $24.96 $140,266 - $332,167	13,308 Added 18.36%	85,807 $904,000
Q2 2020 Aug 14, 2020	SELL	$21.87 - $33.11 $72,499 - $109,759	-3,315 Reduced 4.37%	72,499 $1.77 Million
Q1 2020 May 15, 2020	SELL	$16.25 - $35.28 $2.25 Million - $4.89 Million	-138,700 Reduced 64.66%	75,814 $1.83 Million
Q4 2019 Feb 14, 2020	SELL	$14.17 - $20.3 $46,307 - $66,340	-3,268 Reduced 1.5%	214,514 $3.7 Million
Q3 2019 Nov 14, 2019	SELL	$14.42 - $22.2 $6.17 Million - $9.5 Million	-428,000 Reduced 66.28%	217,782 $3.14 Million
Q2 2019 Aug 14, 2019	SELL	$16.26 - $26.42 $2.84 Million - $4.61 Million	-174,508 Reduced 21.27%	645,782 $12.3 Million
Q1 2019 May 15, 2019	BUY	$15.97 - $22.5 $13.1 Million - $18.5 Million	820,290 New	820,290 $15.4 Million

167

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $310M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.